.png/:/rs=w:1023,cg:true,m)
INHALE: INvestigation of H01 for the Avoidance of Lung Events for COVID-19 patients
We urgently need accessible, effective drugs for COVID-19
Vaccines are unlikely to cover the major centers of the world before the end of 2021
We need an inexpensive, oral medicine to manage COVID-19 lung disease and death worldwide
H01 repurposing a safe, accessible oral drug for COVID-19
New research from the Stanford University School of Medicine suggests an existing EMA-approved oral drug has high potential to treat respiratory distress resulting from COVID-19
H01 (Hymecromone) is approved in multiple countries and available with existing manufacturing capabilities across the globe
Reduce hyaluronan, breathe easier
Hyaluronan is a long-chain glycosaminoglycan secreted in response to SARS-CoV-2 infection. This excess hyaluronan promotes fluid accumulation and gas exchange
H01 (Hymecromone) is an inhibitor of hyaluronan synthesis. EMA-approved and used globally for over 50 years, H01 has a strong record of safety and tolerability in humans
We believe that by repurposing H01 to inhibit hyaluronan synthesis, we can treat COVID-19 associated respiratory distress by reducing fluid accumulation, improving gas exchange, and blood oxygenation
H01: Unique mechanism to addresses unmet need, both in and out of hospital
The INHALE Study is an investigator-initiated, international, multi-center, randomized controlled trial evaluating H01 (Hymecromone) in COVID-19